S-588410 is a Subunit Vaccine owned by Shionogi &, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.
S-588410 is a 5 peptide cocktail vaccine. Upon administration of S-588410, the peptides may stimulate a cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the antigens. This decreases proliferation of susceptible tumor cells.
The revenue for S-588410 is expected to reach a total of $133m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the S-588410 NPV Report.
S-588410 was originated by OncoTherapy Science and is currently owned by Shionogi &.
S-588410 is under development for the treatment of advanced or metastatic bladder cancer, non-small-cell lung cancer, refractory medulloblastoma, pediatric diffuse intrinsic pontine glioma, refractory osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma. It is administered subcutaneously as an emulsion. The therapeutic candidate is a mixed peptide-cocktail vaccine of S-288310 and S-488410 comprising of five human leukocyte antigens (HLA)-A 2402-restricted epitope peptides derived from oncoantigen. The drug candidate is a new molecular entity. It was under development for the treatment of esophageal squamous cell carcinoma.
Shionogi & Overview
Shionogi & (Shionogi) focuses on the research, development, manufacturing, and marketing of pharmaceutical products, diagnostic reagents, and medical devices. It develops innovative products and services in collaboration with its partners. The company offers prescription drugs, over-the-counter (OTC) drugs, and diagnostic products for the therapeutic areas including metabolic disorders, infectious diseases, pain/central nervous system (CNS), and cancer. It offers contract development and manufacturing facilities including all stages from drug development to commercial manufacturing. The company operates a network of subsidiaries, branches, sales offices manufacturing plants, and research laboratories across Japan, China, Taiwan; North America and Europe. Shionogi is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY335,138 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 32.9%, compared to an operating margin of 39.5% in FY2021. In FY2022, the company recorded a net margin of 34.1%, compared to a net margin of 37.6% in FY2021. The company reported revenues of JPY78,939 million for the second quarter ended September 2022, an increase of 9.9% over the previous quarter.
Quick View – S-588410
|Highest Development Stage|